100 related articles for article (PubMed ID: 11762712)
1. Iodine-131 treatment of thyroid papillary carcinoma in patients undergoing dialysis for chronic renal failure: a dosimetric method.
Jiménez RG; Moreno AS; Gonzalez EN; Simón FJL ; Rodriguez JR; Jimenez JC; Córdoba MH; Albertino RV; Jimenez RA
Thyroid; 2001 Nov; 11(11):1031-4. PubMed ID: 11762712
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine treatment of thyroid carcinoma in patients on maintenance hemodialysis.
Daumerie C; Vynckier S; Caussin J; Jadoul M; Squifflet JP; de Patoul N; Wambersie A
Thyroid; 1996 Aug; 6(4):301-4. PubMed ID: 8875750
[TBL] [Abstract][Full Text] [Related]
3. 131I treatment of thyroid papillary carcinoma in a patient with renal failure.
Morrish DW; Filipow LJ; McEwan AJ; Schmidt R; Murland KR; von Westarp C; Betcher KB
Cancer; 1990 Dec; 66(12):2509-13. PubMed ID: 2249192
[TBL] [Abstract][Full Text] [Related]
4. Radiation safety protocol for high dose 131I therapy of thyroid carcinoma in patients on hemodialysis for chronic renal failure.
Modarresifar H; Almodovar S; Bass WB; Ojha B
Health Phys; 2007 Feb; 92(2 Suppl):S45-9. PubMed ID: 17228187
[TBL] [Abstract][Full Text] [Related]
5. Iodine 131 ablation therapy for a patient on maintenance haemodialysis.
Howard N; Glasser M
Br J Radiol; 1981 Mar; 54(639):259. PubMed ID: 7470791
[No Abstract] [Full Text] [Related]
6. [Treatment with (131)I of thyroid remnants in a patient with papillary thyroid carcinoma and end-stage chronic renal failure].
Andres A; Tardín L; Santapau A; Razola P; Prats E; Parra A; Rivas MA; Ruiz P; Alvarez R; Camara A; Banzo J
Rev Esp Med Nucl; 2010; 29(1):32-5. PubMed ID: 20018412
[TBL] [Abstract][Full Text] [Related]
7. (131)I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease.
Ortega AJ; Vázquez RG; Cuenca JI; Brocca MA; Castilla J; Martínez JM; González EN
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):29-33. PubMed ID: 26144699
[TBL] [Abstract][Full Text] [Related]
8. The effects of dialysis on 131I kinetics and dosimetry in thyroid cancer patients--a pharmacokinetic model.
Pahlka RB; Sonnad JR
Health Phys; 2006 Sep; 91(3):227-37. PubMed ID: 16891898
[TBL] [Abstract][Full Text] [Related]
9. Management of thyroid papillary carcinoma with radioiodine in a patient with end stage renal disease on hemodialysis.
Mello AM; Isaacs R; Petersen J; Kronenberger S; McDougall IR
Clin Nucl Med; 1994 Sep; 19(9):776-81. PubMed ID: 7982310
[TBL] [Abstract][Full Text] [Related]
10. Hemodialysis of chronic kidney failure patients requiring ablative radioiodine therapy.
Murcutt G; Edwards J; Boakye J; Davenport A
Kidney Int; 2008 Jun; 73(11):1316-9. PubMed ID: 18354377
[TBL] [Abstract][Full Text] [Related]
11. Radioiodine dosimetry in patients with end-stage renal disease receiving continuous ambulatory peritoneal dialysis therapy.
Kaptein EM; Levenson H; Siegel ME; Gadallah M; Akmal M
J Clin Endocrinol Metab; 2000 Sep; 85(9):3058-64. PubMed ID: 10999786
[TBL] [Abstract][Full Text] [Related]
12. Iodine-131 pharmacokinetics in patients on hemodialysis for end stage renal disease: clinical implications.
Courbon F; Caselles O; Zerdoud S; Duthil P; Regis H; Berry I; Caron P
Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):363-70. PubMed ID: 17043635
[TBL] [Abstract][Full Text] [Related]
13. Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.
Taïeb D; Sebag F; Farman-Ara B; Portal T; Baumstarck-Barrau K; Fortanier C; Bourrelly M; Mancini J; De Micco C; Auquier P; Conte-Devolx B; Henry JF; Mundler O
J Clin Endocrinol Metab; 2010 Jul; 95(7):3283-90. PubMed ID: 20392868
[TBL] [Abstract][Full Text] [Related]
14. The management of well-differentiated thyroid cancer with end-stage renal disease.
Wang TH; Lee CH; Tseng LM; Liu RH
Endocrine; 2003 Aug; 21(3):227-31. PubMed ID: 14515006
[TBL] [Abstract][Full Text] [Related]
15. Effects of hemodialysis on iodine-131 biokinetics in thyroid carcinoma patients with end-stage chronic renal failure.
Yeyin N; Cavdar I; Uslu L; Abuqbeitah M; Demir M
Nucl Med Commun; 2016 Mar; 37(3):283-7. PubMed ID: 26619394
[TBL] [Abstract][Full Text] [Related]
16. Radioactive 131I use in end-stage renal disease: nightmare or nuisance?
Sinsakul M; Ali A
Semin Dial; 2004; 17(1):53-6. PubMed ID: 14717812
[TBL] [Abstract][Full Text] [Related]
17. Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.
Freudenberg LS; Frömke C; Petrich T; Marlowe RJ; Koska WW; Brandau W; Eising EG; Knust EJ; Bockisch A; Jentzen W
Exp Clin Endocrinol Diabetes; 2010 Jul; 118(7):393-9. PubMed ID: 19856257
[TBL] [Abstract][Full Text] [Related]
18. Hemodialysis in patients requiring 131I treatment for thyroid carcinoma.
Fofi C; Festuccia F; Barberi S; Apponi F; Chiacchiararelli L; Scopinaro F; Punzo G; Menè P
Int J Artif Organs; 2013 Jun; 36(6):439-43. PubMed ID: 23653300
[TBL] [Abstract][Full Text] [Related]
19. Use of radioactive iodine I-131 and monitoring of radioactivity in patients with chronic kidney disease on haemodialysis.
Gallegos-Villalobos A; García-López F; Escalada C; Ortiz JJ; Cardona J; Medina A; Portolés J
Nefrologia; 2014 May; 34(3):317-22. PubMed ID: 24798564
[TBL] [Abstract][Full Text] [Related]
20. [Necessity to administer 131I in a patient with papillary thyroid carcinoma undergoing chronic hemodialysis].
Novik V; González R; Díaz M; Vega J
Rev Med Chil; 1998 Jul; 126(7):874-5. PubMed ID: 9830782
[No Abstract] [Full Text] [Related]
[Next] [New Search]
